Company / R&D Expense
QuidelOrtho R&D Expense History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$186.2M
FY2025
5-year range
$84.3M / $245.0M
FY2021-FY2025
Trend
-14.9%
vs FY2024
Sector context
#39 of 105
Health Care
What the data says
At $186M, QuidelOrtho's r&d expense ranks #39 of 105 in the Health Care sector. Declined from $245M to $186M over the past 2 years.
Based on SEC 10-K filings.
$186M in FY2025 with a 5-year CAGR of +17.2%.
Declined from $245M to $186M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -0.3%
- 5-Year CAGR
- +17.2%
- 10-Year CAGR
- -
Sector benchmark
#39 of 105 in Health CareTop 37% of 105This company $186.2M Sector average $284.2M
▼
-34.5% below sector average
Key checks
Key Insights
- 5-year CAGR of +17.2%, indicating consistent growth.
- In FY2025, r&d expense decreased 14.9% year-over-year.
- Ranks #39 out of 105 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 0.10 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $186.2M | -14.9% |
| FY2024 | $218.7M | -10.7% |
| FY2023 | $245.0M | +30.4% |
| FY2022 | $187.9M | +122.9% |
| FY2020 | $84.3M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026